Table 2

Univariate and multivariate analysis for objective response

VariablesUnivariateMultivariate
Full model 1*Full model 2†Reduced model
P valueP valueP valueOR95% CIP value
Age (years)<670.337
≥67
SexMale0.660
Female
ECOG PS0.533
00.271
10.405
≥2Ref.
IMDC risk0.1080.1640.151
Favorable0.4630.5900.470
Intermediate0.0450.4070.582
PoorRef.Ref.Ref.
HistologyClear cell0.0760.1360.119
Non-clear cell
Liver metastasesPresence0.113
Absence
Brain metastasesPresence0.0760.1970.246
Absence
Previous nephrectomyPresence0.0460.3070.267
Absence
No. of previous systemic therapies0.363
10.964
20.294
≥3Ref.
Baseline LDH (IU/L)<3330.513
≥333
Baseline NLR<3.00.454
≥3.0
Baseline CRP level (mg/L)<100.3370.567
≥10
Baseline CRP level (mg/L)Continuous0.1340.371
Early CRP kinetics<0.0010.0020.004<0.001
CRP flare-responder<0.001<0.0010.00139.94.94–911<0.001
CRP responder0.1130.1140.1635.450.69–1150.113
Non-CRP responderRef.Ref.Ref.Ref.
  • *Baseline CRP level was used for a categorical analysis.

  • †Baseline CRP level was evaluated as a continuous variable.

  • CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; No., number; ref., reference.